From Yahoo Finance: 2025-06-18 10:53:00

TransMedics Group Inc. (NASDAQ: TMDX) is making waves as one of the top 10 growth stocks, boasting a 129% share price gain this year, far surpassing its competitors. Revenue surged by 83% in 2024, with expectations of a 31% growth in 2025. The company anticipates a 77% increase in EPS this year and a 38% growth next year. TransMedics continues to lead in organ transplantation innovation, focusing on its National OCS Program to provide comprehensive transplant logistics and technology solutions, aiming for $1.2 billion in revenue by 2028. With plans for new platforms and milestones, the company is set for further growth.



Read more at Yahoo Finance: TransMedics (TMDX) Continues to Scale Innovation in Organ Transplant Care